Advice
in the absence of a submission from the holder of the marketing authorisation:
pembrolizumab (Keytruda®) is not recommended for use within NHSScotland.
Indication under review: in combination with pemetrexed and platinum chemotherapy for the first‑line treatment of adults with unresectable non-epithelioid malignant pleural mesothelioma.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice312KB (PDF)
Medicine details
- Medicine name:
- pembrolizumab (Keytruda®)
- SMC ID:
- SMC2915
- Indication:
In combination with pemetrexed and platinum chemotherapy for the first‑line treatment of adults with unresectable non-epithelioid malignant pleural mesothelioma
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 March 2026